Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - April 14.09.2026 FAPR.LN IE000WX2HZQ7  200,002.00 USD   5,229,202.16   26.146  ...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

NEW HARTFORD, N.Y.--(BUSINESS WIRE)--PAR Technology Corporation (NYSE: PAR), a leading technology provider powering multi-unit operators across restaurant, retail, and large-scale commerce, today announced that Kwik Fill has selected PAR Retail™ as a strategic technology partner. The long-term partnership will help Kwik Fill deliver more relevant, personalized customer experiences while building a stronger foundation for future growth and innovation. Through the partnership, Kwik Fill will leve...

CRANBERRY TOWNSHIP, Pa.--(BUSINESS WIRE)--Westinghouse Electric Company has successfully completed zero-power high-temperature criticality testing for its eVinci™ microreactor, a defining milestone in the program’s build-test-learn development journey. The work was completed in partnership with Los Alamos National Laboratory and the Nevada National Security Site (NNSS) at the National Criticality Experiments Research Center (NCERC), a National Nuclear Security Administration (NNSA) capability i...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC...

OAKLAND, Calif.--(BUSINESS WIRE)--Planted has raised $31.8 million to scale autonomous power deployment, with Piva Capital and RA Capital Management Planetary Health co-leading the round and participation from Breakthrough Energy Ventures, Gigascale Capital, Google, and Khosla Ventures. Power demand is rising faster than new capacity can be built. Solar PV remains the largest contributor to new global electricity supply, hitting a record 664 gigawatts in 2025. Still, the world needs terawatts o...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with world champion skier Lindsey Vonn to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults. Approved by the U.S. Food and Drug Administration (FDA) in January 2025, JOURNAVX marked the first new class of pain medicine in over 20 years — since then JOURNAVX has been prescribed to over...

WASHINGTON--(BUSINESS WIRE)--Deep Fission, Inc. (Nasdaq: FISN) (“Deep Fission” or the “Company”), an advanced nuclear energy company developing small modular pressurized water reactors installed one mile underground, today announced the public release of its Nuclear Safety Design Agreement (NSDA) for the Gravity™ Nuclear Reactor. The U.S. Department of Energy (DOE) approved the NSDA as part of the Company’s Reactor Pilot Program taking place in Parsons, Kansas. The NSDA establishes the safety f...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - July 14.09.2026 FJUL.LN IE000YJBT6I5  100,002.00 USD   2,920,194.24   29.201  ...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...